Roche's Obesity Drug Delivers 22.7% Weight Loss in Mid-Stage Trial, Threatening Competitors
AMGN sits 30% above its 52-week low of $267.83.
Summary
Roche's experimental obesity drug, enicepatide, demonstrated significant efficacy in a mid-stage trial, achieving an average of 22.7% body weight loss in patients after 48 weeks. These strong results introduce a formidable new competitor into the lucrative obesity drug market, where Amgen and Eli Lilly (LLY) are also developing or marketing treatments. The reported weight loss is comparable to or exceeds that of current market leaders, intensifying the competitive landscape and potentially impacting future market share and revenue projections for Amgen's own obesity pipeline.
At the time of this announcement, AMGN was trading at $348.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $188.7B. The 52-week trading range was $267.83 to $391.29. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.